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Abstract
Background: The ‘perfect’ journey through an Irish Methadone Maintenance Treatment Programme (MMTP) would
have a client engage appropriately with all relevant services available to them, inclusive of psychiatry, counselling,
out-reach support, nursing and psychology. Concurrently, a client would ideally adhere to their prescribed
methadone-dosing regimen, until a client is stabilised allowing them to function optimally. At this point, a client
should transfer to the GP community setting. Unfortunately, this fails to occur. To date, very few studies have
specifically investigated the reasons why a cohort of clients remain ‘trapped’ in the high risk, specialist clinical
setting.
Methods: Qualitative detailed semi-structured interviews were undertaken with 17 clients of one of Ireland’s Health
Service Executive (HSE) Drug and Alcohol Services, entitled ‘HSE Mid-West Limerick Drug and Alcohol Service’. Each
client had a severe Opioid Use Disorder (OUD) and clients had spent on average 7.5 years engaging with the
MMTP.
Results: Participants’ life journey prior to an OUD included Adverse Childhood Experiences (ACEs) and early
exposure to illicit drug use. Shared life events resulting in their initiating and sustaining an OUD involved
continuous hardship into adulthood, mental illness and concurrent benzodiazepine use disorder, often resulting in
harrowing accounts of participants’ loneliness and lack of life purpose. Their living environments, an erroneous
understanding of their illness and poor communication with allied health professionals further perpetuated their
OUD. Positive factors influencing periods of abstinence were familial incentives and a belief in the efficacy of
methadone. Clients own suggestions for improving their journeys included employing a multi-sectorial approach to
managing OUD and educating themselves and others on opioid agonist treatments. If clients were not progressing
appropriately, they themselves suggested enforcing a ‘time-limit’ on clients to engage with the programme or
indeed for their treatment to be postponed.
Conclusions: To optimise the functioning of the MMTP, three tasks need to be fulfilled: 1) Reduce the incidences
of ACEs, 2) Diagnose and treat clients with a dual diagnosis 3) Educate clients, their families, the public and allied
health care professionals on all aspects of OUD. A cross- departmental, inter-governmental approach is needed to
address opioid misuse as a societal issue as a whole.
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Background
Opioid Use Disorder (OUD) is worldwide problem [1].
Globally, estimates indicate that 13.5 million people
abuse or misuse opioids, including 9.2 million who have
a specific dependence on heroin [2]. The universal en-
cumbrance of OUD results from its associated health
difficulties, incapacities and death [3]. Worldwide, in
deaths implicating drug use disorders, opioids account
for 76% [2]. In 2016, 10.6 million people worldwide were
known to inject drugs and it is this cohort that endure
the greatest health risks as greater than half of them live
with hepatitis C, and greater than 10% live with HIV [4].
Most recent figures estimate that approximately 3
million people with an OUD reside in the United States
[5]. European statistics reflect that there are approxi-
mately 1.3 million high-risk opioid users in the EU
where opioids are found in 82% of fatal overdoses [6].
The most recent Irish data dates from 2006, and esti-
mates that, at the time, there were approximately 20,790
opioid users in Ireland, a rate of 7.2 per 1000 [7].
It has become increasingly clear that changing the
language of dependence is not just a matter of political
correctness; terminology actually impacts clinical care
[8, 9]. It has finally been acknowledged that to improve
treatment and minimise the stigma surrounding OUD
we must use first-person and medically precise language.
However, if we truly wish to improve results, we should
also amend the language of treatment [10]. Wakeman
argues, and we agree, that the stigma surrounding the
use of pharmacotherapy, in particular opioid agonist
therapy, such as methadone, is more potent and harmful
that the general stigma of addiction. The most widely
held false belief is that opioid agonist medication is sim-
ply a ‘replacement’ or a ‘substitution’. To that end, we
aim to use precise, respectful clinical terminology in this
manuscript, including person-first language and to refer
consistently to medication as a treatment, as in ‘opi-
oid agonist treatment, as opposed to a ‘substitution’
or a ‘replacement’ therapy.
Heroin is the most consumed opioid contributing to
OUD. It is a multi-faceted condition typically needing many
different treatment modalities inclusive of pharmacological
and psychosocial measures [11]. In Europe, 61% of clients
receive methadone, resulting in it being the most frequently
administered agonist therapy [6]. Methadone has ideal
properties for the long-term treatment of OUD: Adminis-
tered orally, it is absorbed slowly through the GI tract.
Typically, a single dose of methadone overpowers the
symptoms of opioid withdrawal for 24–36 h. Methadone
does not produce analgesia, sedation or euphoria [12]. It
follows that the client can function in society without
impairment and experience appropriate pain and emo-
tional reactions. An additional benefit of methadone is
that it over-ride cravings [13].
Over 50 years of research confirms that opioid agonist
treatment with methadone (OATM) is a successful treat-
ment for OUD [14]. Today, Cochrane reviews indicate
strong evidence to support its use [15, 16]. The effective-
ness of OATM in reducing HIV risk behaviour [17],
Hepatitis C transmission [18], as well as overall mortality
[19] is well established. In addition, the literature clearly
shows OATM reduces crime rates [20], improves em-
ployment and family relationships [21] as well as quality
of life [22].
Typically in Europe, specialist out-patient centres ac-
count for the single biggest provider of OATM in terms
of client numbers. The second biggest source of OATM
are health care centres. Included in this category are
General Practitioners (GPs). In large countries such as
Germany and France, these centres are central to the
provision of treatment [6]. Ireland mirrors the current
European structure where methadone has been pre-
scribed since 1992. It is the most common opioid agon-
ist treatment option. The 1998 legislation, the Misuse of
Drugs (Supervision of Prescription and Supply of Metha-
done) Regulations, implemented a specific administrative
structure designed to monitor treatment delivery and in-
dividual trends, the confidential Central Treatment List
(CTL). The legislation also enforced a protocol for the
prescribing of methadone, the Methadone Treatment
Protocol, which provides for the delivery of methadone
treatment in the Irish context. As in Europe, in Ireland,
under this legislation, methadone is provided for in both
specialist out-patient centres and in Primary Care
Centres, both chiefly staffed by GPs.
Under the Irish MMTP, the ‘ideal’ journey through an
Irish HSE Methadone Specialist Centre, such as the one
in this study, would have a client engage appropriately
with all relevant services available to them inclusive of
counselling, out-reach support, nursing and psychology.
Simultaneously, they should properly engage with their
prescribing doctor and adhere to their methadone-dosing
regimen, which is typically increased incrementally until a
level is reached where clients’ OUD is stabilised to allow
them function optimally in society. At this point, a client
should be transferred to the care of a GP in the commu-
nity who should provide the totality of their medical care
including OATM. This would be beneficial from the per-
spective of both the client and the clinic. It would allow the
client greater autonomy in their long-term treatment plan
and allow the clinic to address the needs of those on the
waiting list for treatment initiation. Unfortunately, many
clients never appropriately stabilise to meet the above
criteria.
In Ireland, at year-end 2016, there were 80 HSE Metha-
done Specialist Centres in operation treating 5438 clients
[23]. Of those 5438 clients, only 117 were appropriately
stabilized, and as such, transferred to the lower risk
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community setting [23]. This accounts for only 2.2% of
the potential transferrable client population. Why do cli-
ents not stabilise and progress through the system appro-
priately? Is it behavioral? We must learn how clients view
and understand their surroundings if their behaviour can
ever be interpreted usefully. A benefit of qualitative stud-
ies is that it allows the researcher to analyse and grasp
drug use from the clients’ perspective. To date, such stud-
ies have helped us to destigmatise drug taking and dispel
negative stereotypes. Qualitative research also enhances
our understanding of the theories of dependence and al-
lows us to formulate and assess drug policy and practice
[24]. Therefore, a qualitative analysis of the clients’ behav-
iours in this study should help us understand this failure
in the system better.
Internationally, significant qualitative research with
respect to clients’ perspectives of a MMTP has been
published. Much research has been done focusing on
‘out-of-treatment’ individuals [25] and on retaining
clients in treatment (a significant predictor of outcome)
[26]. For those in treatment, qualitative studies focusing
on clients’ access to treatment [27], level of influence
on their treatment plan [28], quality of life [29] and
their overall satisfaction in Methadone treatment [30]
are well documented. However, very few of these stud-
ies focused on the long-term client failing to progress
optimally through the system. Similarly, in Ireland,
there has been a significant increase in qualitative stud-
ies attempting to address issues with OATM from the
perspective of the client. Nationally, Ireland’s Drug
Strategy (2009–2016) shone a light on the need for
more service user participation and the creation of local
and regional service user platforms. In an urban-based
Irish study, Aoibhinn King, discovered that clients had
little autonomy over the course of their treatment and
had no representative role at service or task force level.
Her study suggests that despite the fact that providers
understand the potential benefits of incorporating client
experiences into the drafting delivery and assessment of
services they remain ‘passive players’ in the equation
[31]. Over the intervening time, Irish research has
attempted to address this deficit. In 2012, Linda Latham
reported on the experiences of service users receiving
methadone treatment in urban general practice in
Dublin and in so doing highlighted the positive influence
of the GP setting in supporting recovery [32].
However, both internationally and nationally very few
qualitative studies specific to the cohort, who remain in
treatment but fail to progress optimally, have been con-
ducted. To date, no Irish study has specifically investi-
gated the reasons why a cohort of clients remains
‘trapped’ in the high risk, specialist clinical setting. These
clients are likely the most complex but in studying their
journey to and through the MMTP, we hope to establish
patterns of similarity, which would flag their high-risk
status on admission and allow us to intervene to opti-
mise their care plan sooner. In doing so, we can opti-
mise the efficiency of the service we provide. This study,
ultimately, wishes to give the clients a voice in address-
ing this complex issue, as their experience of the service
is ultimately, what will determine its success.
Methods
Methodological approach
The epistemological positioning underpinning this quali-
tative study is one of ‘social constructionism’; a term
coined by Norman Blaikie who states; “knowledge is nei-
ther discovered from an external reality nor produced by
reason independent of such a reality. It is the outcome of
people having to make sense of their encounters with the
physical world and with other people.” [33].
Study participants and setting
At year- end 2016, 134 clients were receiving treatment
with the opioid agonist, methadone in the Mid-West of
Ireland’s specialist centre. Of these 134 clients, only 20
(15%) transferred to the lower risk, GP setting in the
community [34].
The Methadone Specialist Centre of the HSE
Mid-West Limerick Service operates 10 methadone
clinics weekly. Each clinic monitors approximately 14
clients. Clients are randomly assigned to their individual
clinic. The first author LM oversees three of these
clinics, resulting in an average exposure to 40 clients
weekly, with a male to female ratio of 3:1. Therefore, this
client exposure reflects a good representative sample of
the overall population of the clinic. The inclusion cri-
teria for this study was that each participant had spent a
minimum of 2 years in the specialist centre. As such, 24
of her clients were eligible for inclusion in the study.
Trust was integral to achieving an honest account of
each participant’s lived experience. The first author LM
worked closely and built a good rapport with all partici-
pants over the last two years. Therefore, the participants
were selected purposively from LM’s client list, choosing
those who had been longest on the programme first to
participate in the study. Many of the potential partici-
pants were illiterate or had only very basic literacy skills
so LM fully explained the information leaflet to them
and asked them to bring it home where they could fur-
ther review it with their families. After the information
giving session, each potential participant was given an
opportunity to think about his or her potential involve-
ment and discuss the research with LM. A minimum
period of one week was allowed before following up
and asking them if they were willing to sign the
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consent form. All clients who were approached agreed
to participate in the study.
Sample size
The method of thematic analysis does not enforce con-
ditions in relation to the size of a given sample. As such,
three main factors shaped the sample size, the complex-
ity of the data expressed by the interviewees, the appear-
ance of shared themes during data analysis and the
pragmatic restrictions of the main author, mainly time
constraints. Accounting for the above, 17 of the 24 cli-
ents were interviewed of which 13 were male and 4 were
female, reflecting a male to female ratio similar to the
overall population of the clinic, 3:1. The 17 clients had
spent on average 7.5 years engaging with the MMTP.
Data collection
Semi-structured interviewing was the method employed
to collect data for this study. This data collection
method enables the researcher and the participant to en-
gage in a real time discussion. It also provides a forum
for original and unexpected issues to arise, allowing the
researcher to subsequently investigate issues in more
detail with further questions should the need arise.
Interview guide
In writing the interview questions, the authors were
cognizant to safeguard participants’ ability to provide in-
depth, complete accounts of their journey to and through
the MMTP. Six key factors (see below) framed the broad
structure of the guide but ensured it was malleable enough
to permit the interviewer to follow-up and further explore
interesting foci as they appeared. The interviewer met with
participants at a time that was most convenient for them. A
reminder phone call to each participant was made 24 h
before the scheduled time.
Interviews
Individual comprehensive semi-structured interviews were
conducted in person by the main author, LM, in a confi-
dential office space situated in the Methadone Specialist
Centre of the HSE Mid-West Limerick Service. At the
outset, LM explained the voluntary nature of the interview
to each participant. Their choice to withdraw at any point
and an explanation of how confidentiality was going to be
upheld throughout was also clarified before both partici-
pant and LM signed the consent form.
LM opened the interview with an icebreaker and then
inquired as to the participants’: 1) Childhood & Educa-
tion, 2) Early Adulthood & Criminality, 3) Drug History
prior to heroin, initiation of heroin and current usage, 4)
Current health, inclusive of mental health, 5) Current
social circumstances (housing, employment, familial
relationships), and 6) Engagement with MMTP (initial &
current). The length of each interview varied, ranging
from 10 to 47 min, with an average of 24 min across the
17 interviews. There were no follow-up interviews.
Audio recordings
Client names were purposely omitted from the recordings.
The digital data was password protected before a profes-
sional transcribing company typed the recordings verbatim.
An offer was extended to all participants to review their
transcripts on their return but all declined this service.
Data analysis Qualitative thematic analysis is a method
for detecting, analyzing, unifying and recounting themes
found within a data set [35] and as such is a perfect fit
for this study. The inductive thematic analysis of this
study, presented in Table 1 below, was undertaken using
Braun and Clarke’s structure of six levels of analysis [35].
Firstly, data familiarization and code generalization was
completed. Then theme search, review and naming was
carried out. An inductive analysis of the themes was
subsequently undertaken. The overall process itself was
both iterative and reflective and involved a continuous
Table 1 The inductive thematic analysis used in this study
Phase 1 Data
Familiarisation
This involved the main author, LM, reading
the first transcript closely a number of times
and checking the transcript back against
the original audio recording for accuracy.
Each review of the recordings provided
some new understandings and LM began
taking personal notes focusing on content,
language use, context, and initial interpretative
comments.
Phase 2 Initial Code
Generalisation
LM coded interesting features of the data
using the computer software NVivo for
qualitative data administration. LM worked
methodically through the full data set. She
gave complete and uniform consideration
to each item, tagging and naming selections
of text with each data item.
Phase 3 Theme search Merging and deviation of themes within the
data were noted, leading to the development
of the next phase, transforming codes into
emergent themes. This involved LM working
more with her notes rather than with the
transcript and again inputting findings into
the NVivo software package.
Phase 4 Theme review LM firstly ensured all coded data extracts
formed a coherent pattern and then
progressed to considering the validity of
each individual theme
Phase 5 Theme naming LM scanned for links between emergent
themes, assembling them according to
conceptual similarities. Each cluster was
then allocated a descriptive label. Using
NVivo allowed for short descriptions of
themes and subthemes, using links to
appropriate passages in the transcript.
Phase 6 Final Report LM produced a report of the analysis
undertaken.
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ebb and flow between the phases. Finally, a summary
report was generated.
Subsequent to this initial assessment, a further sixteen
interviews were undertaken. A similar analysis of the
data from these interviews was conducted. Themes were
reconfigured and re-labelled. Analysis of the 16th and
17th interviews revealed no new data and as a result, no
additional interviews were deemed necessary.
Ethical considerations Participating clients are dependent
on their prescribing doctor to receive their weekly metha-
done prescription and as such, there is an obvious unequal
relationship between them and the first author, LM, which
warrants further explanation. To address this understand-
able bias, prior to conducting the research, the main author
spent 2 years deliberately building a rapport with these cli-
ents, ensuring they trusted her and were fully aware of her
ethical motivations in conducting this research, which ul-
timately aimed to improve the delivery of the MMTP to
better address their needs. In doing so, LM ensured to the
best of her ability that client participation was both op-
tional and truthful.
The potential risks were minimal. However, it was
acknowledged that there was a risk of emotional dis-
tress for the participant during the interview given
that they will be talking about the challenges that are
inherent in being a long-term client of a MMTP. The
main author and the Multi-Disciplinary Team MDT
worked together to make sure to minimise this risk and
dealt with any upset that occurred both immediately and
in the longer-term by offering regular follow-up counsel-
ling services. Reassurance of confidentiality were given and
participants were assured that they could cease the inter-
views at any point if they so wished. As their clinician, the
first author having the overall responsibility for their health
from a Methadone perspective monitored the health of
participants during the study.
Following the University of Limerick Records Manage-
ment and Retention Policy, E-transcripts were stored on
a password -protected computer and hard copies were
locked in a cabinet in the main author’s office. University
Hospital Limerick’s Research Ethics Committee on
December 13th 2016 granted full ethical approval for
this study: REC Reference 131/16.
Results
On initial analysis, an enriching insight into the per-
sonal journeys of each client to and through the
Mid-West of Ireland’s MMTP emerged from the data.
Common themes across their life journey prior to an
OUD were documented. Shared life events resulting
in their initiating and sustaining an OUD were also
captured. Subsequent analysis revealed both negative
factors perpetuating their continued opioid usage and
positive factors encouragingly influencing periods of
abstinence. Both sets of factors were recorded. Finally,
clients own suggestions for improving their journeys
were identified.
Personal journey to and through the MMTP
Their journeys, though each unique, had common chrono-
logical sub-themes, which are schematically shown in Fig. 1
and elaborated on below.
Adverse Childhood Experiences & Early exposure to illicit
drug use
Childhood adversity was an exceptionally common oc-
currence across the interviewees, occurring both inside
Fig. 1 Clients’ personal journeys to and through the MMTP in the HSE Mid-West Limerick Service
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and outside the home. Reports of both physical and
verbal abuse were common, with particular emphasis on
paternal physical abuse. Alcoholism was also reported to
be prevalent within the home, which was often coupled
with reports of domestic violence. The clients docu-
mented further reports of experimenting with cannabis,
gas, butane, LSD and solvent abuse. Mental illness per-
meated these households adding to the adversities of
childhood. As a result, some clients were placed in the
care of the State.
“I was in care for a bit & stuff. My mam died and my
father couldn’t handle me. I had psychoses.”
Interviewee 14
Abuse, outside the home was also common, both for
those in institutional care
“Life there was horrible, horrible, horrible, horrible,
some terrible things, Oh I don’t even want to talk
about them...” Interviewee 9
and for those living in the general community
“When I was young like there used to be a man with a
black fluffy dog the whole time. I would always see
him like, but he was just a bad man. Then he did bad
things to me”. Interviewee 17
Reports of bullying outside the home and parental
separation within the home were also documented.
Having a family member in incarceration was also
common. Coupled with this, most interviewees re-
ported exposure to a culture of illicit drug use from
a very young age.
“When I was 10 or so, my mother and my father
were working. I used to go into the drinks cabinet
with an empty bottle of lemonade and fill it up
with all different spirits…. When I was about 12 or
13, me and my friend found a load of Roche 30s
[flurazepam monohydrochloride tablets of 30mg
strength] …. we took the full box between us. And
then I ended up I woke up in St. Johns hospital…
they said that like my heart stopped for a couple
of seconds.” Interviewee 12
Continuous hardship from childhood into adulthood
Misfortune and difficulties continued to permeate
their lives from childhood onwards. Often, their in-
ability to cope with these relentless stressors resulted
in commencement of heroin abuse and indeed fre-
quently perpetuated its continued use thereafter. The
brief excerpts below summarises the struggles clients
face on a daily basis and explain their regular relapses
with addiction.
“My sister got murdered, she got shot dead. The hit
was meant for me. My other brother got stabbed to
death…. My other brother, he done 9 years in prison
and he got out and died in the shower of a heart
attack…. My little brother just died, meningitis in the
brain got him. My other brother he is a schizophrenic.
He’s in and out of prison. He lives in a mental hospital
now. The most stable influence in my life was the
presence of my father. Unfortunately, he passed away
in 2016, when I was in incarceration” Interviewee 11
Mental illness, inclusive of psychoses, depression and
anxiety
More frequently than not, reports of mental illness were
recorded in tandem with these clients’ heroin addiction.
Psychoses, depression and anxiety disorders were the most
common mental illnesses documented. These illnesses
may have been present from a young age, as interviewee 2
reports, “I suffered from psychosis since the age of fifteen.
Schizophrenia psychosis I have” or indeed brought on later
in adulthood as a result of harrowing adversities.
“I lost two children in 9 days. My son, he hung himself
in prison, three days left in his sentence. My daughter
committed suicide 9 days later. She went out, bought
Xanax (alprazolam), and took the whole lot and she
took about nine bags of heroin as well and just threw
herself off the bridge. Afterwards, I tried to kill myself.”
Interviewee 9
Clients often expertly captured their misdiagnosis by
health care professionals due to suffering from both
their heroin dependenceand a mental illness. They might
feel that their psychiatric team only focused on their
dependenceand not depression and mental illness.
“Yeah, I had depression there when I was out on bail
for killing, that really got me down. I was in the acute
psychiatric unit for about two, three months. They [the
psychiatric team] were, they were mixing the two for
me, they were trying to say that it was all got to do
with the drugs and everything in my own heart and
soul like it was because of what happened, you know”.
Interviewee 3
Illicit benzodiazepines usage
Not altogether surprisingly, an overwhelming proportion
of interviewees were dually addicted to benzodiazepines
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(BDZ). More often than not clients were buying these
on the city’s black market. Due to the high demand for
BDZ outstripping local supply, the market was becoming
more dependent on foreign suppliers, and purchasing
them on the internet was commonplace. Clients have no
idea what they are purchasing, as these tablets are
illegally manufactured and so do not resemble
prescribed BDZ in shape or size and indeed are often
laced with other drugs.
“At the moment, Benzos are a big thing in Limerick.
They’re Spanish supposed to be, now there’s two different
types, there’s ones that say U94 on them. You can bust
them in four, they’re supposed to be two milligrams and
the shape of them is very funny, I’d say it would be very
hard to copy them though. And then there’s other ones
that says Xanax on the front of them, but they’re real
thick and chunky and they have two on the back, they’re
supposed to be two milligrams as well, but I took them
and they made my urine dirty here” [A ‘dirty’ urine refers
to a urine-testing positive for opiates] Interviewee 7
The use of BDZ to enhance the effect of heroin was also
apparent. Chaotic, alarming use of BDZ was evident,
where the risk of accidental overdose was undisputed.
“I put them [BDZs] into the pot and inject them with
the heroin so I inject them both together” Interviewee 12
“I am after taking 6-7 sticks [Sticks are a potent form
of street Xanax, approximate equivalent to 2 mg
Xanax] now [before interview]. I could take 20-30 of
them a day. I buy sticks over Xanax because they are
stronger. They are sent back from Spain; they are
charging a fortune for them. I take Upjohn 90s [1mg
Xanax] as well, maybe 10-15 a day” Interviewee 15
Often, their supply of BDZ was from the same supplier
as their heroin and as such, BDZ usage perpetuating
heroin usage was evident. The cost of feeding their dual
dependencealso surfaced as a stressor in their lives.
Lack of life purpose and loneliness
Clients expressed a significant lack of purpose in their
lives. Boredom was a dominant reference. and was
described as a reason for their continued heroin use.
“Boredom is a big part I think, just sitting down at
home with nothing to do thinking I will smoke that
now it might knock me out” Interviewee 16
Loneliness was a prevailing emotion linked to this sub-
theme. Lack of employment, a known contributor to the
economic burden of this disease, had a significant
negative impact on clients’ self-worth. Many blamed
having a criminal record for their unemployment. Inabil-
ity to work due to disabilities related to their heroin
abuse was also evident. Lack of motivation was also
evident.
“It’s very hard, motivation is lacking big time, yeah.
I’m on disability at the moment, it’s because I’ve had
DVTs in both legs over injecting [into the groin]. I
don’t think I am fit enough to work… and with a
criminal record” Interviewee 3
Negative factors which influence clients’ journeys
Turbulent living environment
On analyzing the data, three specific unstable living con-
ditions emerged which perpetuated the continued use of
heroin, living with an addict, living in hostel accommo-
dation and finally being homeless. Living with an addict
resulted in clients stating they often sought heroin on
behalf of their partners as opposed to fueling their own
habit. This was reported as a ‘safety’ measure as they
worried if their partners attempted to seek heroin on
their own behalf they would end up in trouble, be it,
assaulted themselves by mixing with an undesirable
crowd or committing a crime, such as robbery to fuel
their habit on their own.
“I would be hoping that it don’t come through like but
if I don’t get it he would probably end up robbing
something, do you know I mean? So it’s actually
protecting him by getting it off my sister. Keeping him
in doors and away from danger” Interviewee 1
Homelessness was also reported as an environment
that fueled their need to continuously use. Motivation
was hugely lacking in the homeless cohort, as being
homeless secludes you from many basic needs.
“If you haven’t got your own address you can’t get any
help, medically, doctors, on assistance on anything. No,
you can’t even get the dole. That is one of the main
reasons I continue to use” Interviewee 2
Finally, the environment most associated with contin-
ued use or frequent relapse was for clients living in
hostel accommodation.
“I’m in a hostel now and there’s two people dealing
fucking heroin. It’s full of addicts. I can’t open my eyes, I
can’t go outside my room without bumping in to
someone and they’re either talking about drugs or doing
drugs or a way of getting them, and it was just a matter
of time before my brain... gives in” Interviewee 3
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Peer influence
Data analysis confirmed that clients cited the term
‘friend’, ‘mate’ or ‘cellmate’ as the method by which all
were first introduced to heroin. Though all lives differed
greatly on their individual journeys, peer influence on
initiation of their addiction, was the one constant vari-
able. Thereafter, continued friendships with other drug
takers perpetuated their dependence.
“I don’t really have any friends who don’t take drugs”
Interviewee 16
The only potential solution cited to address this issue
was to attempt to completely isolate themselves from
their social scene.
“I’ve isolated myself from all other addicts like, do you
know, I don’t talk to any of them, I don’t, I’ve blocked
all the drug dealers’ numbers”. Interviewee 6
However, given that the majority of these clients live in
hostel, shared accommodation with other drug addicts
isolating themselves from their peers is near impossible
as is evident from the quotes in the ‘turbulent living
conditions’ section above.
Erroneous understanding of their illness
Uniformly, clients had a poor understanding of the
chronicity of their illness, the likelihood for long-term
OATM or indeed of the rationale for using methadone
as a medical intervention in their disease management.
Clients were asked to reflect on how long they thought
they would need treatment for when they first engaged
with the programme. Their answers varied from 3 to 6
months. However, in reality, the average time spent in
OATM across the 17 clients was 7.5 years. That said,
when asked re the likelihood for them needing ‘long--
term’ opioid agonist therapy, the vast majority of clients
were resolutely confident that they would not require
‘long-term’ medication. Over the last 12 years, inter-
viewee 4, had repetitively engaged and re-engaged with
the programme, relapsing regularly during the time but
when probed as to why he believed he would not need
‘long-term’ therapy answered confidently, “I think I’m
passed that, you know, I think I am”.
Clients’ confidence in remaining opiate free was dis-
proportionate to their actual achievement. At the time
of interview, interviewee 11, had succeeded in not using
heroin for just one week but was adamant she would re-
main opiate free forever more. Not only so, but because
of her week’s sobriety she now wished to cease metha-
done completely. When probed if she knew of anyone
who had successfully ceased methadone and remained
opiate free thereafter she denied knowledge of it. Yet
was confident in her own success without methadone.
“Well I am clean now a full week. It’s my first time I
am clean and I am staying clean…. I don’t want it
(the methadone) I am sick of it, it’s not for me… To be
honest with you. I can’t think of anyone there that
came off Methadone and stayed clean” Interviewee 11
When asked re their level of education with regard to
methadone itself participants were uniformly poorly
educated. Education levels of clients’ families were also
poor, which in turn resulted in lack of familial support for
the treatment.
“I got given a leaflet, so I just read through that, you
know.’ (I learned) a little bit off YouTube” interviewee
8. “No, no one explained to me how methadone works”
Interviewee 9
“My mam, she hates the stuff, she hates it because she
thinks it’s the Devil’s drink” Interviewee 7
Interviewee 12 was embarrassed by the fact that the
public was, “paying taxes for keeping people on metha-
done”. When challenged and asked if the public should
not view opiate dependence as a chronic illness, much
like diabetes, and requiring methadone was much like
diabetics needing insulin he defended the public’s per-
ception of heroin dependence:
“You are not born with the choice of diabetes but you are
born with the choice of not taking heroin” Interviewee 12
Poor communication with allied health professionals
The majority of clients reported a fragmented, poor and
sometimes fractious relationship with their General Prac-
titioners. They reported the fear of being stigmatised as
the reason for hiding their heroin dependenceand engage-
ment with the MMTP from their GP.
“I didn’t tell my GP I had a heroin problem because I,
I wasn’t telling anybody that I had a heroin problem. I
was so anxious and nervous that I was going to get
judged” Interviewee 8
However, on finding out the client was on the MMTP
their relationship immediately disintegrated. The GP
recalled all the times she prescribed opiate based medi-
cations for the client because of his reported pains and
began to doubt the need or truth in his needing it. As a
result, she felt she could no longer remain his GP. As a
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result, the client reported feeling abandoned and isolated
from the health care system.
“I felt like a complete, excuse me, piece of shit. When I
walked outside that door I never felt so lonely and so
scared in my life’.... I’ve no GP from then till now”
Interviewee 8
Reports of a similarly tenuous, disjointed relationship
with local counselling and mental health services were
documented. Furthermore, poor inter-communication
between allied health professionals was also evident.
Interviewee 12 reported suffering with panic attacks. His
GP referred him to the local psychiatric hospital where
benzodiazepines were prescribed as a treatment modal-
ity. However, he reports his GP not agreeing with this
treatment plan.
“When I came back to my GP he then took me off the
benzos. I told him I still get panic attacks but he said,
“it’s all in your mind” and to just exercise your way
out of it like” Interviewee 12
Positive factors, which influence a clients’ journey
Structured living environment
Often, the more regularised their living conditions were,
the greater their likelihood was of remaining opiate free.
Three specific environments were tabulated; prison, hos-
pital and when housed in a drug free environment. Inter-
viewee 13 reported finding the structure and governance
that prison offered, “behind a steel door”, a welcomed re-
prieve from his chaotic life which fueled his drug habit.
Reports of purposefully getting caught committing crimes
to ensure imprisonment were documented, as clients knew
the strict regime of prison had the potential to help them
succeed in their quest for sobriety.
“ I was using gaol as a rehab, do you know, I was
going out, committing crimes and getting caught on
purpose just to go in to gaol to get off the gear. I
couldn’t get off it you know on my own outside. Gaol
saved me enough of times. It worked for me. It gave me
structure that you don’t have on the outside”
Interviewee 4
Interviewee 11 felt prison had saved her life. She was
also so desperate to escape the clutches of her dependen-
cethat she voluntarily presented herself for incarceration.
“If I didn’t go to prison, I would have been found dead
to be honest with you. I handed myself into the prison
or else I would have fell to the ground and just died”
Interviewee 11
In addition, when given the opportunity to move from
hostel accommodation, as documented above, to a drug-
free apartment successful cessation was noted.
“Ever since we got in to that apartment, we had no
one around us that was on heroin, so I think that’s
what kind of helped us” interviewee 5
Other ‘controlled’ environments where successful re-
prieve from their dependenceoccurred was when hospi-
talised for prolonged periods or indeed when housed in
a specific drug-detoxification centre.
Familial incentive
At various points in their journeys, these clients had pe-
riods of sobriety driven by certain incentives, mainly family
members, particularly children or younger siblings. Their
dependence results in their journeys being chaotic and
quite often unmanageable but their overall ultimate wish in
life is for simplicity. Their aspirations are basic, a normal fa-
milial home with full access to their children, where the
can function as a stable parent and ultimately gain the re-
spect of their children, siblings and other family members.
“My ultimate goal is to, just to have my family back
around me and get the house back to normal”
interviewee 4
Interviewee 12, was motivated by his daughter’s ac-
knowledgement that her classmates were referring to
him derogatively as a “junkie”.
“That was kind of like one of the nails in the coffin
for me, it was like going, Jesus Christ I had better
get off this stuff…. But it’s an uphill struggle”
interviewee 12
Interviewee 11 did manage to remain opiate free when
in prison and is aware of the benefits of a structured
routine, as a result feels a detoxification centre may be
her best option to rid herself of her addiction.
“I would go into treatment at some point. To get my
kids back, to live normally, just being a normal mother
for my kids, that’s all I want” interviewee 11
Belief in methadone
An extremely favorable relationship with regard to the
pharmacological properties of methadone was reported,
particularly in the early phases of treatment. The reports
ranged from the very basic to the more complex. Clients
were exceptionally grateful for methadone’s ability to
prevent the symptoms of withdrawal, often giving a very
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honest description of the positive effects with regard to
this. Beyond this basic function, other clients viewed
methadone as a step closer to a more ‘normal life’ as it
releases them from the grip of their disease and allows
them to choose their path in life. Some viewed metha-
done as quite simply, lifesaving.
“It just gives you time, it gives you a choice,
methadone actually gives you the choice to take or
leave heroin” interviewee 3
“I went on methadone because if I didn’t I would’ve
ended up dead”. Interviewee 7
Clients’ personal proposals for improving their journey
Final data analysis identified clients’ personal proposals
for improving their journey. At the end of each inter-
view, each client was given the opportunity to suggest
changes they would implement to the programme to op-
timise its effectiveness. The most common client derived
suggestion was contentious as it involved limiting client
time on the programme.
Enforce time limits on phases of their journey within the MMTP
Interviewees suggested a very strict induction phase of
treatment for new clients with a well thought out plan
to enforce it. All new clients would be limited on the
programme to a 5-week treatment plan, increasing their
dose incrementally by 5mls to a maximum of 50mls.
“If you don’t bring back a clean sample after this, that
is it for you, we will talk to you next month. We have
someone else in line who needs to try this. Try it that
way and see if it works or if it doesn’t” Interviewee 2
Other clients not only supported the above measures
but took it one step further by suggesting to also in-
crease the weekly urine testing to twice weekly admitting
that once weekly testing can be orchestrated by the cli-
ents to give false negative samples. When questioned as
to the effect such sanctions would have on their own en-
gagement with the programme most clients felt such
sanctions would be inappropriate for their particular
journey, citing ‘long-term’ engagement in the programme
as a justifiable reason not to adhere to same.
“But when you get to fifteen to twenty years like I am
using methadone you just need it” interviewee 14
Employ a multi-sectorial approach
Clients strongly advocated for the integration of their
opioid agonist treatment with other relevant services,
such as psychiatric services, GP medical care and hous-
ing services. The primary advantage to a unified ap-
proach is that clients attending the clinic would have
easier access to these services thereby improving engage-
ment with these supports.
“I just think ye yourselves doctors, and psychiatrists,
and housing [representatives] if you could roll all that
into this clinic it would be fucking dynamite. Can you
image the amount of people in Ireland you would be
helping? The organisation you create would be
phenomenal it would be phenomenal to be supported
by the government” Interviewee 2
Provide education
This subtheme imbued many of the transcripts.
References were made to educating the public and a
specific suggestion was to revise our wording of
methadone as a ‘substitute’ as this terminology had
exceptionally negative connotations and clients be-
lieved as a result, fueled the publics’ misunderstand-
ing of the treatment.
“Educate people, because when people hear you’re on
methadone they just assume you’re on heroin and they
don’t see it as a treatment, they see it as a substitute”
Interviewee 8
Clients also felt society’s youth needed to be properly
educated re the dangers of drug misuse.
“Oh Jesus the kids definitely need to be educated. A lot
of these kids wound up taking drugs they didn’t know’
[what they were taking]”. Interviewee 12
Discussion
The aim of this study was to gain insight into how the
current treatment of OUD could be improved for those
who fail to progress appropriately over time from the
acute clinical setting to that of the local community GP
setting within the Irish MMTP. As is evident above, data
analysis highlighted many themes contributing to this
failure but unfortunately, to sufficiently address all of
these themes is beyond the scope of this manuscript.
Therefore, for the purpose of this research manuscript,
we will focus on further exploring three specific themes;
ACEs and stress in later adulthood, dually diagnosed
clients and education. The reason for focusing on these
themes is that they focus on one aspect of pre OUD,
childhood adversity and its impact on coping with stress
in later adulthood, one during OUD, concurrent mental
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health illness and finally one which addresses not only
the individual but the need for their families, the general
public and health care professionals to better educate
themselves on all aspects of OUD if the burden of this
disease is ever to be addressed appropriately. After
expanding on each theme specific recommendations as
to how to ameliorate them are then suggested.
Adverse childhood experiences (ACEs) and stress in later
adulthood
The CDC study was the original and remains one of the
most comprehensive research study on childhood neg-
lect and abuse and their impact on subsequent health
and well-being in adulthood [36]. It showed a definite
causal relationship between the depth of exposure to
family dysfunction or abuse during childhood and many
of the risk factors for the leading causes of adult mortal-
ity, inclusive of illicit drug abuse. Nearly all clients in
our study identified with childhood trauma.
Over the intervening 20 years, ACEs continued to be of
increasing international concern and consequently there is
a continuously growing wealth of research, which validates
that chronic stressful experience in childhood, can lead in-
dividuals on a health harming life course, inclusive of illicit
drug use [37]. Studies specific to illicit drug use continue
to find remarkably high percentages of childhood
trauma, specifically emotional, sexual and physical
abuse, in drug dependent clients. The risk of early ex-
perimentation with substance abuse increased 2–4
times for each ACE and nearly 2/3rds of injection drug
use can be linked to ACEs [38].
1n 2015, Public Health Wales distributed an inter-
nationally validated questionnaire to 2028 Welsh adults.
It examined their current health behaviours and their
exposure to ACEs [39] using an internationally validated
questionnaire [40]. Compared with no ACEs, those with
4 or more ACEs were 16 times more likely to have
experimented with crack cocaine or heroin. As is evident
from our study above, many clients experienced adversi-
ties in childhood and all nine of the adversities listed in
the Welsh study were documented in the transcripts in
this study inclusive of, Sexual abuse, Physical abuse, Ver-
bal abuse, Domestic Violence, Parental separation, Mental
illness, Alcohol abuse, Drug abuse and Incarceration.
Children of those affected by ACEs are at a heightened
risk of exposing their own children to ACEs [41]. This
perpetuation of ACEs is commonly known as the ‘cycle of
violence’. [42]. This continuous cycle can lock generation
into OUD. It follows that stopping ACEs in one gener-
ation or minimising their impact on children can help not
only those individuals but also their offspring. Such a cycle
of childhood adversity can lock successive generations of
families into opioid dependence. Consequently, preventing
ACEs in a single generation or reducing their impact on
children can benefit not only those individuals but also fu-
ture generations. Research shows that there is a significant
reduction in opioid use amongst adolescent patients re-
ceiving OAT which further compounds the need to inter-
vene as early as possible in their treatment [43]. Public
Health will play a central role in breaking the cycle of vio-
lence but they will require help and support from health
care services such as Drug and Alcohol Services [39].
Trauma in early childhood impacts how we respond to
stress throughout our lives and as stress plays an integral
role in developing and sustaining dependence [44], it
merits a brief look here. Exposure to early stressors in
life, such as, poor parenting, family dysfunction, and ad-
verse neighbourhood characteristics creates a lower “set
point” for a child’s internal stress system.
It has been found that early life trauma can alter the
brain’s stress regulatory system, which influences an in-
dividual’s ability to regulate emotion and respond to fear
[45]. Consequently, individuals may be more vulnerable
to health harming behaviours in later adulthood. This
predisposition is developed further when trauma is
subsequently encountered in later life [46].
If an individual has a heightened stress response, they
are likely to attribute a high worth to substances that
offer temporary relief such as opioid misuse. In contrast,
activities, which typically offer satisfaction, such as, mean-
ingful, familial relationships, are undervalued because in
the client’s life they have never been fulfilling [47]. It is
well established that as dopamine levels decrease, the
craving for drug use increases. Stress reduces the function
of dopaminergic receptors in the emotional circuits of the
forebrain [48] and consequently increases the long term
craving for opioids. The reward value in drug use is en-
hanced by stress and even after periods of abstinence,
stress can provoke relapse [49].
In the treatment of OUD, incorporating a focus on
stress and its management could improve treatment out-
comes [44]. There is a considerable public health cost
associated with drug use and such improvements would
pay a considerable dividend.
Dual diagnosis
Dual diagnosis is, as defined by the Royal College of Psy-
chiatrists, 2002, “the co-existence of both mental health
and a substance use disorder including both drugs and
alcohol” [50]. Each disorder in itself is chronic and re-
lapsing, travels an independent course and is capable of
influencing the other disorder. Individuals experiment-
ing with recreational drug use are more at risk for devel-
oping an OUD if they have a separate psychiatric
condition [51]. Likewise, compared to the general popu-
lation, clients diagnosed with OUD, have a greater risk
of developing an independent psychiatric disorder, in-
cluding a dependence on other substances [52]. As was
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evident in the analysis of the transcripts from our study,
there is a complex relationship between the two as diag-
noses range from 1) A primary psychiatric disorder with
secondary substance use disorder, 2) A primary sub-
stance use disorder with psychiatric complications, 3) A
concurrent substance use and psychiatric disorder, and
4) An underlying traumatic experience resulting in both
substance use disorder and mood disorder.
Implications of a dual diagnosis are far reaching.
Co-occurring psychiatric and SUDs are notoriously diffi-
cult to manage clinically. Adherence to treatment and
its subsequent effectiveness are negatively impacted due
to the comorbidity and ultimately service user morbidity
and mortality are increased [53]. For clients with a dual
diagnosis, optimizing treatment of their psychiatric dis-
orders is essential to improving the outcome of their
opioid use disorder. Benzodiazepine (BDZ) usage was
particularly chaotic in the clients of this study. Research
indicates that a comorbid tranquilizer use disorder is
linked to higher rates of persistent opioid use [54].
Screening and addressing a co-morbid BDZ use disorder,
in collaboration with clients’ GPs and psychiatric team
members should improve their clinical outcome. Fur-
thermore, the earlier in life one begins to use opioids,
the increased likelihood of presenting with a concurrent
psychiatric illness [55]. Awareness of this risk posed
should better our ability to identify clients at an in-
creased risk of dual-diagnosis in our clinical practices.
Two main barriers in addressing the needs of dually
diagnosed clients lie in firstly diagnosing the problem
and secondly collaborating with relevant stakeholders to
ensure their treatment plan is optimised. A chaotic life-
style is a contributory factor in failing to diagnose
co-existing needs. This can affect individuals making
and adhering to medical appointments or even availing
of community-based services. The result of which is that
those whose opioid use coexists with a mental health
often reach crisis point. The existing health and social
care system needs to change. Services are ill equipped
and under resourced to deal with more than one problem
at a time. Instead, the system responds to support clients’
primary need be it drug, alcohol or mental health. Many
services are provided by the NGO sector who may be
working in isolation from statutory providers.
Education
The neurobiology of dependence is exceptionally complex
and as a result poorly understood, even amongst profes-
sionals in the medical community. Clinicians need to im-
part evidence-based truths with regard to the addictive
process in opioid use disorder to not only their clients but
also their clients’ families and the public to optimise the
functioning and overall success of any MMTP. Develop-
ments in our understanding of the neurobiological
processes that arise following chronic and acute opioid ad-
ministration have helped enhance our scientific under-
standing of how dependence develops.
We must focus on the individual and not his or her
disease in the treatment of OUD. However, grasping an
understanding of the neurobiology of drug dependence
can be extremely valuable to the clinician. It can offer an
insight into individual behaviours and problems, help es-
tablish person centred attainable goals and define the ra-
tionale for treatment [56]. Individuals who are taught
about the origins of dependence can benefit from under-
standing the biological basis of their illness and its need
for long-term, often life-long therapy to negate its effects
centrally. The term ‘psychoeducation’ in opioid depend-
ence refers to a form of communication between clin-
ician and client that acknowledges the client’s role in
understanding and dealing with the realities of their ill-
ness. The overall purpose to get the client to willing ad-
here to their treatment regimen while reducing or
counteracting the factors that contribute to relapse.
Clients in treatment are typically driven by acutely
pressing conditions such as the symptoms of withdrawal
and have limited insight. They understand that craving
is the leading contributory factor for relapse but lack
long-term disease awareness, which means they deny the
chronic nature of their dependence. Clients live in the
here and now and solely focus on their immediate
circumstances. They equate spontaneous short-term ab-
stinence with full remission and any subsequent relapse
is viewed as an isolated episode [57].
As is evident in our study it is when clients are re-
lieved of their acute discomfort is when insight into their
dependence regresses. They believe they are able to
manage their cravings and opioid use. They struggle to
accept any relapse prevention perspectives and fail to
see drug dependence as a chronic relapsing disorder.
The main aim of psycho education is to develop a higher
level of client insight and understanding.
It was apparent in the above study that clients had many
‘misconceptions’ about OATM. Given our understanding
of the neurobiology of drug dependence and the effective-
ness of methadone in its treatment clinicians should ac-
tively engage in psycho-education to prevent relapse.
Despite the overwhelming evidence that OUD is an
enduring, relapsing brain disorder the stigma associated
with opioid agonist treatment, such as methadone, is
clearly prevalent in today’s society. Unfounded opinions
about ‘addiction’ are widely rooted in the cultural main-
stream and are particularly harmful as they confound
clients’ misconception of their illness.
Conclusion
There is no denying the toll of OUD is tremendous. In giv-
ing a voice to the most complex of clients within the Irish
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Drug and Alcohol service, this manuscript highlighted
many aspects of their lives before and during treatment,
which need to be addressed in order to optimise their qual-
ity of life. In doing so, this may well reduce the burden of
OUD on society as a whole, for the individual, their fam-
ilies and our communities. This manuscript explored three
specific areas of redress, ACEs, dually diagnosed clients
and societal education.
The MMTP is ideally placed to work collaboratively
with public health, to access the most vulnerable and high
risk of individuals subjected to ACEs and offer additional
supports to meet their complex needs. To address stress
in later adulthood, we recommend resourcing specific
treatments for the management of stress in clients with an
OUD, which will have far-reaching benefits. If we are ever
going to effectively treat OUD, tailored interventions for
the treatment of clients’ stress from psychologists, coun-
sellors, psychiatrists and General Practitioners (GPs), all
working collaboratively, are needed.
Goals for effective change for dually diagnosed clients
should focus on collaboration between and education of
all stakeholders (both statutory and non-statutory). It is
vital that mental health staff receive drug and alcohol
awareness training. Similarly, staff of the drug and alco-
hol services should receive mental health training. This
would enable staff to better refer and work collabora-
tively. Information sessions offered by counsellors and
psychologists would be beneficial. Multi-disciplinary
forums would allow staff to tease out challenges and
capitalise on opportunities with clients. The advan-
tages of well-trained staff are obvious as inevitably
this will improve results and make for a more effi-
cient health care system.
From an education perspective, we must ensure to
educate clients appropriately as to the neurobiology of
their illness, the pharmacokinetics of methadone and its
role in OUD. We must as Dana Hunt argued over 20
years ago, “change the view of methadone maintenance
within the heroin using community from that of a passive
process of “giving up” to an assertive lifestyle of active re-
covery” [58].
Another strategy that could be adopted is to create
and disseminate short information packets for use by
outreach services to counter ‘street myths’ on metha-
done and other OATs in dependence. Ensure that scien-
tifically grounded information on methadone, as a
treatment modality for OUD is included within the
in-service training programmes of all clinics. Integrate
information on OUD treatment into the curricula of na-
tional medical schools. Provide regular training and up-
date sessions for not only General practitioners in the
community but all allied health professional training
programmes involved with the drug and alcohol services
on the treatment of OUD and its advancements.
Public awareness as to disease process of depend-
ence as well as the therapeutic benefit of treatments
such as methadone must be publicised. Create, roll
out and assess a public education campaign incorpor-
ating the voice and face of the ordinary person on
opioid dependence and its treatment. Increase access
to information on OUD and its treatment in main-
stream health care facilities [59].
A cross- departmental, inter-governmental approach
to address substance misuse as a societal issue as a
whole is needed. Subsequent work needs to be done on
addressing vulnerable children’s exposure to illicit drug
use, concurrent BZDs use in individuals with OUD, their
housing conditions and their lack of life purpose and
loneliness.
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